Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Sokolov

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Diabetes, Obesity & Metabolism|November 21, 2018
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitusVictor Sokolov, Tatiana Yakovleva, Shinya Ueda, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 14, 2025
An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus ErythematosusAlina Volkova, Victor Sokolov, Florencia Tettamanti, et al.
Clinical Pharmacology and Therapeutics|June 19, 2025
Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host DiseaseYan-Ou Yang, Alina Volkova, Victor Sokolov, et al.
Diabetes, Obesity & Metabolism|December 28, 2020
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetesMillie Shah, Leonid Stolbov, Tatiana Yakovleva, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 1, 2020
A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human BeingsVeronika Voronova, Victor Sokolov, Amani Al-Khaifi, et al.
Journal of Lipid Research|July 12, 2019
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemiaVictor Sokolov, Gabriel Helmlinger, Catarina Nilsson, et al.
Frontiers in Pharmacology|December 15, 2022
Evaluation of therapeutic strategies targeting BCAA catabolism using a systems pharmacology modelVeronika Voronova, Victor Sokolov, Yannick Morias, et al.
American Journal of Hypertension|September 11, 2023
Model-Based Assessment of the Reference Values of CAVI in Healthy Russian Population and Benchmarking With CAVI0Tatiana Safronova, Anna Kravtsova, Sergei Vavilov, et al.
British Journal of Clinical Pharmacology|June 2, 2022
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT intervalDinko Rekić, Ivan Azarov, Jane Knöchel, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 18, 2020
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology ModelingVictor Sokolov, Tatiana Yakovleva, Lulu Chu, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|November 21, 2018
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitusVictor Sokolov, Tatiana Yakovleva, Shinya Ueda, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 14, 2025
An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus ErythematosusAlina Volkova, Victor Sokolov, Florencia Tettamanti, et al.
Clinical Pharmacology and Therapeutics|June 19, 2025
Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host DiseaseYan-Ou Yang, Alina Volkova, Victor Sokolov, et al.
Diabetes, Obesity & Metabolism|December 28, 2020
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetesMillie Shah, Leonid Stolbov, Tatiana Yakovleva, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 1, 2020
A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human BeingsVeronika Voronova, Victor Sokolov, Amani Al-Khaifi, et al.
Journal of Lipid Research|July 12, 2019
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemiaVictor Sokolov, Gabriel Helmlinger, Catarina Nilsson, et al.
Frontiers in Pharmacology|December 15, 2022
Evaluation of therapeutic strategies targeting BCAA catabolism using a systems pharmacology modelVeronika Voronova, Victor Sokolov, Yannick Morias, et al.
American Journal of Hypertension|September 11, 2023
Model-Based Assessment of the Reference Values of CAVI in Healthy Russian Population and Benchmarking With CAVI0Tatiana Safronova, Anna Kravtsova, Sergei Vavilov, et al.
British Journal of Clinical Pharmacology|June 2, 2022
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT intervalDinko Rekić, Ivan Azarov, Jane Knöchel, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 18, 2020
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology ModelingVictor Sokolov, Tatiana Yakovleva, Lulu Chu, et al.
Pageof 3